SARS-CoV-2 Variants by Whole-Genome Sequencing in a University Hospital in Bangkok: First to Third COVID-19 Waves.
COVID-19
SARS-CoV-2
disease severity
genetic diversity
mutation
whole-genome sequencing
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
21 Apr 2023
21 Apr 2023
Historique:
received:
18
02
2023
revised:
30
03
2023
accepted:
17
04
2023
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerged globally during the recent coronavirus disease (COVID-19) pandemic. From April 2020 to April 2021, Thailand experienced three COVID-19 waves, and each wave was driven by different variants. Therefore, we aimed to analyze the genetic diversity of circulating SARS-CoV-2 using whole-genome sequencing analysis. A total of 33 SARS-CoV-2 positive samples from three consecutive COVID-19 waves were collected and sequenced by whole-genome sequencing, of which, 8, 10, and 15 samples were derived from the first, second, and third waves, respectively. The genetic diversity of variants in each wave and the correlation between mutations and disease severity were explored. During the first wave, A.6, B, B.1, and B.1.375 were found to be predominant. The occurrence of mutations in these lineages was associated with low asymptomatic and mild symptoms, providing no transmission advantage and resulting in extinction after a few months of circulation. B.1.36.16, the predominant lineage of the second wave, caused more symptomatic COVID-19 cases and contained a small number of key mutations. This variant was replaced by the VOC alpha variant, which later became dominant in the third wave. We found that B.1.1.7 lineage-specific mutations were crucial for increasing transmissibility and infectivity, but not likely associated with disease severity. There were six additional mutations found only in severe COVID-19 patients, which might have altered the virus phenotype with an inclination toward more highly pathogenic SARS-CoV-2. The findings of this study highlighted the importance of whole-genome analysis in tracking newly emerging variants, exploring the genetic determinants essential for transmissibility, infectivity, and pathogenicity, and helping better understand the evolutionary process in the adaptation of viruses in humans.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerged globally during the recent coronavirus disease (COVID-19) pandemic. From April 2020 to April 2021, Thailand experienced three COVID-19 waves, and each wave was driven by different variants. Therefore, we aimed to analyze the genetic diversity of circulating SARS-CoV-2 using whole-genome sequencing analysis.
METHODS
METHODS
A total of 33 SARS-CoV-2 positive samples from three consecutive COVID-19 waves were collected and sequenced by whole-genome sequencing, of which, 8, 10, and 15 samples were derived from the first, second, and third waves, respectively. The genetic diversity of variants in each wave and the correlation between mutations and disease severity were explored.
RESULTS
RESULTS
During the first wave, A.6, B, B.1, and B.1.375 were found to be predominant. The occurrence of mutations in these lineages was associated with low asymptomatic and mild symptoms, providing no transmission advantage and resulting in extinction after a few months of circulation. B.1.36.16, the predominant lineage of the second wave, caused more symptomatic COVID-19 cases and contained a small number of key mutations. This variant was replaced by the VOC alpha variant, which later became dominant in the third wave. We found that B.1.1.7 lineage-specific mutations were crucial for increasing transmissibility and infectivity, but not likely associated with disease severity. There were six additional mutations found only in severe COVID-19 patients, which might have altered the virus phenotype with an inclination toward more highly pathogenic SARS-CoV-2.
CONCLUSION
CONCLUSIONS
The findings of this study highlighted the importance of whole-genome analysis in tracking newly emerging variants, exploring the genetic determinants essential for transmissibility, infectivity, and pathogenicity, and helping better understand the evolutionary process in the adaptation of viruses in humans.
Identifiants
pubmed: 37111512
pii: pathogens12040626
doi: 10.3390/pathogens12040626
pmc: PMC10146024
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand
ID : 14-63
Références
Gene Rep. 2021 Mar;22:100997
pubmed: 33319124
Signal Transduct Target Ther. 2022 Apr 26;7(1):138
pubmed: 35474215
Sci Rep. 2020 Oct 6;10(1):16602
pubmed: 33024144
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Virus Evol. 2022 Aug 26;8(2):veac080
pubmed: 36533153
Microbiol Immunol. 2021 Oct;65(10):405-409
pubmed: 33835528
Front Med (Lausanne). 2021 Sep 01;8:737602
pubmed: 34540874
Viruses. 2022 Oct 27;14(11):
pubmed: 36366473
Viruses. 2022 Nov 12;14(11):
pubmed: 36423117
Int J Antimicrob Agents. 2021 Feb;57(2):106272
pubmed: 33347989
JAMA Netw Open. 2022 Sep 1;5(9):e2232760
pubmed: 36136332
Mol Biol Evol. 2021 Jun 25;38(7):3022-3027
pubmed: 33892491
Sci Rep. 2021 Jul 1;11(1):13705
pubmed: 34210996
Nat Med. 2021 Sep;27(9):1495-1496
pubmed: 34400842
Front Microbiol. 2021 Oct 18;12:753823
pubmed: 34733263
BMJ Open. 2022 Feb 8;12(2):e055474
pubmed: 35135773
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Microb Genom. 2021 Dec;7(12):
pubmed: 34870573
Microorganisms. 2021 Sep 13;9(9):
pubmed: 34576839
Methods. 2022 Jul;203:282-296
pubmed: 34547443
Viruses. 2022 Sep 08;14(9):
pubmed: 36146796
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
PLoS One. 2021 Jan 26;16(1):e0238665
pubmed: 33497392
Emerg Infect Dis. 2021 May;27(5):1492-1495
pubmed: 33900193
Microorganisms. 2021 Aug 05;9(8):
pubmed: 34442750
Signal Transduct Target Ther. 2022 Jan 27;7(1):26
pubmed: 35087058
Clin Infect Dis. 2022 Aug 24;75(1):e1120-e1127
pubmed: 34487522
Sci Rep. 2022 Sep 14;12(1):15456
pubmed: 36104358
Front Med (Lausanne). 2022 Jan 28;9:830942
pubmed: 35155505
BMJ Glob Health. 2021 Jul;6(7):
pubmed: 34285042
Nat Med. 2021 Sep;27(9):1518-1524
pubmed: 34504335
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018
pubmed: 34982465
Epidemiol Infect. 2021 Apr 30;149:e110
pubmed: 33928885
mSystems. 2021 Feb 23;6(1):
pubmed: 33622851
Int J Infect Dis. 2022 Sep;122:123-129
pubmed: 35562044
Adv Prev Med. 2021 Oct 08;2021:5807056
pubmed: 34659835